Mark Bunnage

Executive Vice President and Chief Scientific Officer · Vertex Pharmaceuticals

Biopharmaceuticals

Mark Bunnage is executive vice president and chief scientific officer of Vertex Pharmaceuticals. A medicinal chemist by training, he spent twenty years at Pfizer before joining Vertex in 2016 and advancing through its research leadership.

Last reviewed: Oct 31, 2026

Mark Bunnage

Executive Vice President and Chief Scientific Officer
Vertex Pharmaceuticals

Last Reviewed: October 31, 2026

Executive Summary

Mark Bunnage is executive vice president and chief scientific officer of Vertex Pharmaceuticals. A medicinal chemist by training, he spent twenty years at Pfizer before joining Vertex in 2016 and advancing through its research leadership.

Career Highlights

  • Joined Vertex in 2016 as head of its Boston research site.
  • Previously led global research at Vertex before becoming chief scientific officer.
  • Held medicinal chemistry leadership roles during a twenty-year Pfizer career.

Professional Journey

After doctoral research at Oxford, Bunnage worked with K. C. Nicolaou at the Scripps Research Institute as a NATO postdoctoral fellow. He joined Pfizer’s laboratories in Sandwich, England, as a medicinal chemist in 1996.

His Pfizer responsibilities expanded into scientific leadership. By 2010, he was executive director and head of medicinal chemistry at the Sandwich laboratories. In 2011, he moved into vice president-level chemistry leadership in Cambridge, Massachusetts. His work included small-molecule discovery for inflammation, immunology and rare diseases and chemistry support for Pfizer’s Centers for Therapeutic Innovation.

Bunnage joined Vertex in 2016 as head of its Boston research site. He subsequently became senior vice president and head of global research, broadening his remit across the company’s research organization.

As chief scientific officer, he leads research strategy across Vertex’s sites, alongside data and computational sciences, preclinical sciences and external innovation. His work at Vertex has included contributions to the discovery of inaxaplin and research programs in kidney disease and cystic fibrosis. During his Vertex tenure, the research organization also advanced the gene-editing therapy Casgevy and the non-opioid pain medicine Journavx into clinical development. Earlier Pfizer work contributed to candidates that became the medicines Cibinqo and Litfulo.

Beyond company leadership, Bunnage has served as a visiting professor of chemistry at Oxford and edited New Frontiers in Chemical Biology. His scientific work includes publications and patents, and he is a fellow of both the Royal Society of Chemistry and the Royal Society of Biology.

Education

Bunnage earned a Bachelor of Science in chemistry from Durham and a D.Phil. in chemistry from Oxford. He subsequently conducted postdoctoral research at the Scripps Research Institute.